Better access to health innovation is Kyriakides’ top priority (and hardest task)

By |september 11th, 2019|breast cancer, Cancer Plan, drugs price, EFPIA, EPHA, Health Commissioner, innovation in pharmaceuticals, medicines affordability, News, Stella Kyriakides|

With increased powers, Health Commissioner-designate Stella Kyriakides is tasked with striking a difficult balance between making sure there is a steady supply of affordable medicines and ensuring that EU pharma industry remains a world leader in innov...

Komentarji so izklopljeni za Better access to health innovation is Kyriakides’ top priority (and hardest task)

Pharma industry raises the alarm about stockpiling of generic drugs

By |januar 29th, 2019|EFPIA, generic drugs, generic medicine, generics, News, SPC manufacturing waiver|

The industry of innovative medicines is concerned with a recent vote in the European Parliament on the stockpiling of generic drugs, saying that it causes uncertainty over innovation in the pharmaceutical field.

Komentarji so izklopljeni za Pharma industry raises the alarm about stockpiling of generic drugs

Discussion heats up over stockpiling of generic drugs under patent protection

By |januar 21st, 2019|drug innovation, EFPIA, generic drugs, generic medicine, News, SPC manufacturing waiver|

The Commission has announced its intention to add a manufacturing waiver to supplementary protection certificates (SPC), as part of its upgraded 2015 Single Market Strategy.

Komentarji so izklopljeni za Discussion heats up over stockpiling of generic drugs under patent protection

Protecting the spark, avoiding the storm

By |november 29th, 2018|EFPIA, News, SPC manufacturing waiver|

Every new treatment, every transformational shift in the outlook for patients starts with the spark of an idea, writes Nathalie Moll.

Komentarji so izklopljeni za Protecting the spark, avoiding the storm

Does fast-track drugs approval in EU run too fast?

By |oktober 25th, 2018|drug approval, EFPIA, EMA, new drugs, News, PRIME, Rare Diseases Europe|

More than two years after its launch, the EU's fast-track approval process for marketing new drugs, called PRIME, is broadly welcomed by patients and industry, walking the fine line between patients' safety and expediency, and between the need to foste...

Komentarji so izklopljeni za Does fast-track drugs approval in EU run too fast?

Drug industry reacts to Oxfam’s allegations of tax-dodging

By |september 19th, 2018|Big pharma, EFPIA, News, tax avoidance|

Four of the world’s biggest pharma companies appear to hide their profits in tax havens, according to a report published by Oxfam on Tuesday (18 September). Businesses said they are in the clear.

Komentarji so izklopljeni za Drug industry reacts to Oxfam’s allegations of tax-dodging

EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

By |julij 3rd, 2018|Big pharma, drug innovation, drug pricing, EFPIA, generic drugs, intellectual property rights, News, Orphan drugs, pharmaceutical companies, SPC manufacturing waiver|

The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.  

Komentarji so izklopljeni za EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

Time to end fragmentation of EU healthcare, experts say

By |maj 8th, 2018|Celgene, drug innovation, drug pricing, EFPIA, News|

Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.

Komentarji so izklopljeni za Time to end fragmentation of EU healthcare, experts say

Pharma boss: Incentives based on outcomes will optimise EU healthcare

By |maj 7th, 2018|efficiency in healthcare, EFPIA, Healthcare and austerity, healthcare systems, News, pharmaceutical companies, SPC manufacturing waiver|

An outcomes-based approach for incentives in the pharmaceutical sector would help optimise the entire healthcare systems, Nathalie Moll told EURACTIV.com in an interview.

Komentarji so izklopljeni za Pharma boss: Incentives based on outcomes will optimise EU healthcare

Celgene boss: Chronic diseases will bankrupt Europe if incentives are dropped

By |december 7th, 2017|drug pricing, EFPIA, healthcare access, intellectual property rights, News|

Alzheimers, diabetes, cancer and other non-communicable diseases will bankrupt Europe if we don’t keep the incentive frameworks alive and well, Mark Alles told EURACTIV.com in an interview.

Komentarji so izklopljeni za Celgene boss: Chronic diseases will bankrupt Europe if incentives are dropped